2,6-DHBA tends to reduce glucose tolerance, at least in short-term treatment [36], does not readily inhibit the mitochondria (our work and [13], [16]), and in our studies, it did not inhibit G6Pase promoter activity, nor did it reduce glucose output from hepatocytes; however, in the context of obesity and long-term drug treatment, beneficial effects of both drugs on inflammation may be exhibited, allowing comparison with pharmacology restricted to SA, such as the uncoupling effect that we have studied. This evidence concerns the gene G6PC1 and obesity disorder.